Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Alkermes plc

A Decade of SG&A Expenses: Neurocrine Biosciences, Inc. vs Alkermes plc

In the competitive landscape of biopharmaceuticals, understanding the financial strategies of industry leaders is crucial. Over the past decade, from 2014 to 2023, Neurocrine Biosciences, Inc. and Alkermes plc have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Neurocrine Biosciences, Inc. has seen a staggering increase of nearly 4,800% in SG&A expenses, starting from a modest $18 million in 2014 to an impressive $888 million in 2023. In contrast, Alkermes plc's expenses have grown by approximately 245%, from $200 million to $690 million over the same period. This divergence highlights Neurocrine's aggressive expansion and investment in administrative capabilities, while Alkermes maintains a steady growth trajectory. These insights provide a window into the strategic priorities of these companies, reflecting their commitment to innovation and market presence.